FKBP51在乳腺癌中的表达及其临床意义

Expression of FKBP51 in breast cancer and its clinical significance

目的探讨FK506结合蛋白51(FKBP51)在乳腺癌中的表达及其与临床病理特征和预后的相关性。方法选取140例乳腺癌(包括导管内癌和非特殊性浸润性导管癌,源自西安艾丽娜生物科技有限公司芯片和山东省立医院病理科)和作为对照的21例乳腺纤维腺瘤(源自山东省立医院病理科)组织,采用免疫组化Eli VisionTM法检测其FKBP51及AR、ER、PR、HER-2、P53、Ki-67的表达,分析乳腺肿瘤中FKBP51的表达情况及其与临床病理特征和预后的相关性。结果 FKBP51在乳腺癌中表达阳性率为36.4%,明显低于乳腺纤维腺瘤(66.7%),差异有统计学意义,P=0.008;乳腺纤维腺瘤、导管内癌和非特殊性浸润性导管癌中FKBP51表达阳性率分别为66.7%、43.5%和35.0%,差异有统计学意义(P=0.023)。在非特殊性浸润性导管癌,FKBP51的表达水平与组织学分级、分子分型呈负相关(β=-1.156,P=0.023;r=-0.302,P=0.001);与PR指数呈正相关(β=1.210,P=0.000);与临床TNM分期、淋巴结转移数目以及AR、ER指数不相关(P>0.05)。结论 FKBP51高表达的乳腺癌细胞预后较好,有可能作为乳腺癌治疗和预后判断指标。

Objective To investigate the expression of FK506 binding protein 51(FKBP51) in breast cancer and its clinical significance. Methods The expression of FKBP51, AR, ER, PR, HER-2, P53 and Ki-67 was detected by immunohistochemical Eli VisionTM method in 140 cases of breast cancer(included intraductal carcinoma and invasive ductal carcinoma, and derived from Xi’an alina biotechnology co.’s chip and pathology department of Shandong provincial hospital), and the 21 cases of fibroadenoma(derived from pathology department of Shandong provincial hospital) being as control groups, to analyze the correlation of FKBP51 expression in breast cancer with clinicopathological features and its relationship with prognosis. Results The positive expression rate of FKBP51 in breast cancer was 36.4%, was obviously lower than that in breast fibroadenoma(66.7%), with significant statistically difference, P=0.008; The positive expression rate of FKBP51 in fibroadenoma, intraductal carcinoma and invasive ductal carcinoma was respectively 66.7%, 43.5% and 35.0%, with significant statistically difference, P=0.023. In invasive ductal carcinoma, the expression of FKBP51 was negatively correlated with histological grade, molecular typing(β=-1.156, P=0.023; r=-0.302, P=0.001), and positively correlated with PR(β=1.210, P=0.000). There was no significant difference between the expression of FKBP51 and clinical tumor TNM stage, lymphatic metastasis number, AR and ER(P>0.05). Conclusion The breast cancer cell with the higher expression of FKBP51 may have the better prognosis, and FKBP51 may inhibit the proliferation of breast cancer cell through steroid hormone receptor pathway.